EWTX
Edgewise Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | +8 | 40.34M | $1.62B | +13 | −4 |
| Q1 2026 | 81 | +4 | 39.90M | $1.24B | +9 | −6 |
| Q4 2025 | 77 | +2 | 40.83M | $1.01B | +3 | — |
| Q3 2025 | 14 | +1 | 17.98M | $291.62M | +1 | −1 |
| Q2 2025 | 11 | -4 | 17.73M | $232.39M | — | −4 |
| Q1 2025 | 12 | -2 | 5.61M | $123.36M | — | −2 |
| Q4 2024 | 14 | 0 | 7.38M | $197.14M | +1 | −1 |
| Q3 2024 | 13 | +3 | 6.24M | $166.42M | +3 | — |
| Q2 2024 | 10 | — | 8.30M | $149.57M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 2.35M | — | $42.31M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.67M | — | $30.13M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.67M | — | $30.13M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Viking Global Investors ✦ | 1.48M | — | $26.68M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 1.15M | — | $20.63M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 493.85K | — | $8.89M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 493.85K | — | $8.89M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Marshall Wace ✦ | 415.72K | — | $7.49M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 362.58K | — | $6.53M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 311.48K | — | $5.61M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 311.48K | — | $5.61M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 49.60K | — | $893,242 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 23.09K | — | $416,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 213 holders, 118.39M shares, $3.71B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.92K sh · $126,704
Officer · 2.17K sh · $95,075
Officer · 304 sh · $13,529
Officer · 150 sh · $6,666
Officer · 2.48K sh · $108,154
Officer · 2.84K sh · $124,303
Officer · 2.78K sh · $121,463
Officer · 104 sh · $4,620
Officer · 800 sh · $35,614
Officer, Director · 8.78K sh · $383,254
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology